W. Akahata, Z. Y. Yang, H. Andersen, S. Sun, H. A. Holdaway et al., A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection, Nat Med, vol.16, pp.334-338, 2010.

I. C. Albulescu, A. Tas, F. E. Scholte, E. J. Snijder, and M. J. Van-hemert, An in vitro assay to study chikungunya virus RNA synthesis and the mode of action of inhibitors, J Gen Virol, vol.95, pp.2683-2692, 2014.

M. Bourjot, P. Leyssen, J. Neyts, V. Dumontet, and M. Litaudon, Trigocherrierin A, a potent inhibitor of chikungunya virus replication, Molecules, vol.19, pp.3617-3627, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01011997

S. Brandler, C. Ruffie, C. Combredet, J. B. Brault, V. Najburg et al., A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus, Vaccine, vol.31, pp.3718-3725, 2013.

L. J. Chang, K. A. Dowd, F. H. Mendoza, J. G. Saunders, S. Sitar et al., Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial, Lancet, vol.384, issue.9959, pp.2046-2052, 2011.

A. Chattopadhyay, E. Wang, R. Seymour, S. C. Weaver, and J. K. Rose, A chimeric vesiculo/alphavirus is an effective alphavirus vaccine, J Virol, vol.87, pp.395-402, 2013.

W. Chen, S. S. Foo, A. Taylor, A. Lulla, A. Merits et al., an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection, J Virol, vol.89, pp.581-593, 2015.

T. Couderc, F. Chretien, C. Schilte, O. Disson, M. Brigitte et al., A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease, PLoS Pathog, vol.4, issue.2, p.29, 2008.
URL : https://hal.archives-ouvertes.fr/pasteur-01402310

T. Couderc, N. Khandoudi, M. Grandadam, C. Visse, N. Gangeux et al., Prophylaxis and therapy for Chikungunya virus infection, J Infect Dis, vol.200, pp.516-523, 2009.

R. Edelman, C. O. Tacket, S. S. Wasserman, S. A. Bodison, J. G. Perry et al., Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218, Am J Trop Med Hyg, vol.62, pp.681-685, 2000.

E. C. Farnon, J. J. Sejvar, and J. E. Staples, Severe disease manifestations associated with Acute chikungunya virus infection, Crit Care Med, vol.36, issue.9, pp.2682-2683, 2008.

K. Gammon, The cost of chikungunya to Jamaica. Jamaica Observer, 2014.

D. Hallengard, M. Kakoulidou, A. Lulla, B. M. Kummerer, D. X. Johansson et al., Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice, J Virol, vol.88, pp.2858-2866, 2014.

S. B. Halstead, Reappearance of chikungunya, formerly called dengue, Americas. Emerg Infect Dis, vol.21, pp.557-561, 2015.

V. R. Harrison, K. H. Eckels, P. J. Bartelloni, and C. Hampton, Production and evaluation of a formalin-killed Chikungunya vaccine, J Immunol, vol.107, pp.643-647, 1971.

L. Josseran, C. Paquet, A. Zehgnoun, N. Caillere, A. Le-tertre et al., Chikungunya disease outbreak, Reunion Island, Emerg Infect Dis, vol.12, issue.2, pp.1994-1995, 2006.

P. Kaur, M. Thiruchelvan, R. C. Lee, H. Chen, K. C. Chen et al., Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression, Antimicrob Agents Chemother, vol.57, pp.155-167, 2013.

M. Khan, S. R. Santhosh, M. Tiwari, L. Rao, P. V. Parida et al., Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells, J Med Virol, vol.82, pp.817-824, 2010.

K. Labadie, T. Larcher, C. Joubert, A. Mannioui, B. Delache et al., Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages, J Clin Invest, vol.120, issue.3, pp.894-906, 2010.

J. Lemant, V. Boisson, A. Winer, L. Thibault, H. André et al., Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in, Crit Care Med, vol.36, issue.9, pp.2536-2541, 2005.

N. H. Levitt, H. H. Ramsburg, S. E. Hasty, P. M. Repik, F. E. Cole et al., Development of an attenuated strain of chikungunya virus for use in vaccine production, Vaccine, vol.4, pp.157-162, 1986.

K. Mallilankaraman, D. J. Shedlock, H. Bao, O. U. Kawalekar, P. Fagone et al., A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates, PLoS Negl Trop Dis, vol.5, issue.928, 2011.

D. Mavalankar, P. Shastri, T. Bandyopadhyay, J. Parmar, and K. V. Ramani, Increased mortality rate associated with chikungunya epidemic, Emerg Infect Dis, vol.14, issue.3, pp.412-415, 2008.

T. E. Morrison, Reemergence of chikungunya virus, J Virol, vol.88, pp.11644-11647, 2014.

K. Plante, E. Wang, C. D. Partidos, J. Weger, R. Gorchakov et al., Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism, PLoS Pathog, vol.7, issue.1002142, 2011.

L. Pohjala, A. Utt, M. Varjak, A. Lulla, A. Merits et al., Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays, PLoS One, vol.6, 2011.

K. Ramsauer, M. Schwameis, C. Firbas, M. Mullner, R. J. Putnak et al., Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-inman trial, Lancet Infect Dis, vol.15, issue.5, pp.519-527, 2015.

C. J. Roy, A. P. Adams, E. Wang, K. Plante, R. Gorchakov et al., Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose, J Infect Dis, vol.209, pp.1891-1899, 2014.

N. E. Rulli, M. S. Rolph, A. Srikiatkhachorn, S. Anantapreecha, A. Guglielmotti et al., Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis, J Infect Dis, vol.204, pp.1026-1030, 2011.

C. Schilte, T. Couderc, F. Chretién, M. Sourisseau, N. Gangneux et al., Type I IFN controls chikungunya virus via its action on non-hematopoietic cells, J Exp Med, vol.207, issue.2, pp.429-442, 2010.

C. Schilte, F. Staikowsky, T. Couderc, Y. Madec, F. Carpentier et al., Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study, PLoS Negl Trop Dis, vol.7, issue.3, p.2137, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01189712

M. K. Soumahoro, P. Y. Boelle, B. A. Gauzere, K. Atsou, C. Pelat et al., The chikungunya epidemic on La Réunion Island in 2005-2006: a cost-of-illness study, PLoS Negl Trop Dis, vol.5, issue.6, p.1197, 2011.

F. Staikowsky, F. Talarmin, P. Grivard, A. Souab, I. Schuffenecker et al., Prospective study of Chikungunya virus acute infection in the Island of La Reunion during the 2005-2006 outbreak, PLoS One, vol.4, issue.10, p.7603, 2009.

S. D. Thiberville, V. Boisson, J. Gaudart, F. Simon, A. Flahault et al., Chikungunya fever: a clinical and virological investigation of outpatients on Reunion Island, PLoS Negl Trop Dis, vol.7, issue.1, p.2004, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01307675

S. D. Thiberville, N. Moyen, L. Dupuis-maguiraga, A. Nougairede, E. A. Gould et al., Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy, Antiviral Res, vol.99, issue.3, pp.345-370, 2013.

I. Tretyakova, J. Hearn, E. Wang, S. Weaver, and P. Pushko, DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice, J Infect Dis, vol.209, pp.1882-1890, 2014.

E. Wang, E. Volkova, A. P. Adams, N. Forrester, S. Y. Xiao et al., Chimeric alphavirus vaccine candidates for chikungunya, Vaccine, vol.26, pp.5030-5039, 2008.

S. C. Weaver and N. L. Forrester, Chikungunya: evolutionary history and recent epidemic spread, Antiviral Res, vol.120, pp.32-39, 2015.

G. D. Zakaib, Virologists form Global Virus Response Network, Nature News Blog, 2011.